Show simple item record

dc.creatorTai, Wanbo
dc.creatorHe, Lei
dc.creatorPu, Jing
dc.creatorZhang, Xiujuan
dc.creatorVoronin, Denis
dc.creatorJiang, Shibo
dc.creatorZhou, Yusen
dc.creatorDu, Lanying
dc.date.accessioned2020-07-22T22:42:33Z
dc.date.available2020-07-22T22:42:33Z
dc.date.created2020-03-19
dc.identifier.issn2042-0226spa
dc.identifier.otherhttps://www.nature.com/articles/s41423-020-0400-4spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11002
dc.format.extent8 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectProteína RBDspa
dc.titleCharacterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccinespa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.subject.keywordRBD proteinspa
dc.identifier.doihttps://doi.org/10.1038/s41423-020-0400-4spa
dc.description.abstractenglishThe outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record